|
|
Viramune (Nevirapine)
| Brand Name: |
Viramune |
| Generic Name: |
Nevirapine, NVP |
| Adult Single Dose: |
One 200-mg tablet (once a day) for
14 days then one 200-mg tablet (twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NNRTI |
The Basics
- An Overview of Viramune (Nevirapine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Nevirapine (Viramune) (June 28, 2008)
To read PDF, click here
From AIDS InfoNet
- Viramune (Nevirapine, NVP) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Viramune (Nevirapine) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Patient Information About Viramune (Nevirapine) (PDF) (June 2007)
From Boehringer Ingelheim
- Viramune (Nevirapine) (May 2005)
To read PDF, click here
From The Center for AIDS
- Viramune and Women in the News (March/April 2005)
A breakdown of the risks and benefits of taking nevirapine.
In Survival News, from AIDS Survival Project
- Nevirapine (Viramune) (January 19, 2005)
From U.S. Food and Drug Administration
- Drug Interactions: Nevirapine (August 2004)
From Project Inform
News
- Summary of FDA Advisory on Nevirapine in Women With a CD4 Count Over 250 (February 28, 2005)
In AIDS Treatment News, from AIDS Treatment News
- FDA Public Health Advisory for Nevirapine (Viramune) (January 19, 2005)
From U.S. Food and Drug Administration
- Nevirapine Misinformation: Will It Kill? (December 31, 2004)
From AIDS Treatment News
- South Africa Drops Recommendation of Single-Dose Nevirapine Monotherapy for Pregnant Women (July 14, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Nevirapine Precautions Published (February 27, 2004)
New instructions provide information on who is most at risk for rare but serious liver-related side effects.
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine-Based Fixed-Dose Combination Antiretrovirals in Resource-Limited Settings (May 2003)
Excerpted from HIV & AIDS Treatment in Practice.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Pharmaceutical Giant to Let Generic Company Manufacture Its AIDS Drug (October 15, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Boehringer Ingelheim Pharmaceuticals Withdraws AIDS Drug Application (March 25, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Let Nevirapine Do What It Does Best (March 2002)
Why recent doubts about widespread use of the drug are unfounded.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- St. John's Wort Found to Lower Nevirapine Levels (March 2, 2001)
From Canadian AIDS Treatment Information Exchange
- Severe Nevirapine Rash Found More Likely in Women Than Men (January 22, 2001)
From Canadian AIDS Treatment Information Exchange
- Nevirapine Warning on Post-Exposure Prophylaxis (January 12, 2001)
In AIDS Treatment News, from AIDS Treatment News
- Sex Differences in Nevirapine Rash and Hepatitis (January 2001)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Viramune May Cause Liver Damage (January 2001)
In Survival News, from AIDS Survival Project
- Roxane Issues Strengthened Warning of Viramune-Related Liver Problems (December 15, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- More Caution With Nevirapine (December 11, 2000)
From Canadian AIDS Treatment Information Exchange
- Nevirapine (Viramune) Strengthens Warning on Liver, Skin Toxicities (November 17, 2000)
In AIDS Treatment News, from AIDS Treatment News
- Nevirapine, Prednisone, and Rash (October 2000)
In Project Inform Perspective, from Project Inform
- Nevirapine (Viramune): European Warning (May 5, 2000)
In AIDS Treatment News, from AIDS Treatment News
- Major Advance in Protecting Newborns: One Nevirapine Dose Cuts Infection in Half (July 16, 1999)
From AIDS Treatment News
For Pregnancy/Newborns
- Six-Month Delay in Onset of Nevirapine-Based Antiretroviral Therapy Can Prevent Drug Resistance Following Single-Dose Nevirapine During Labor, Study Says (January 11, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Nevirapine Still at Center of MTCT Controversy (Summer 2005)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Combination Therapy Might Be Better Choice Than Nevirapine Alone to Prevent Vertical HIV Transmission, Researchers Say (February 25, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- The Risk of NNRTI Resistance Following Perinatal Nevirapine and Ramifications for Subsequent Antiretroviral Therapy Success (January 2005)
Part of HIV JournalView's Top 10 Research Reports of 2004.
From The Body PRO
- Nevirapine Misinformation: Will It Kill? (December 31, 2004)
From AIDS Treatment News
- Questions and Answers About the Safety and Effectiveness of Nevirapine in Preventing Mother-to-Infant Transmission of HIV (December 17, 2004)
The United States responds to concerns over the Ugandan HIVNET 012 study.
From U.S. National Institute of Allergy and Infectious Diseases
- Project Inform Defends the Use of Single-Dose Nevirapine to Prevent Mother-to-Child Transmission of HIV (December 15, 2004)
To read PDF, click here
From Project Inform
- Comments on Nevirapine Resistance, by Global Strategies for HIV Prevention (November/December 2004)
Global Strategies is an international nonprofit organization focused specifically on aiding women and children at risk for HIV.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Pediatric AIDS Foundation on Single-Dose Nevirapine (November/December 2004)
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Single-Dose Drugs May Be Effective, But They Can Jeopardize Long-Term Therapy (November/December 2004)
Recent studies bring potentially bad news for HIV drugs with long half-lives.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Single-Dose Theory: A Historical Overview of the Use of Nevirapine to Prevent Mother-to-Child HIV Transmission (November/December 2004)
Includes a critical analysis of the late-2004 controversy over the drug's use in pregnant women.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Time to Move On: More Questions About Single-Dose Nevirapine (November/December 2004)
Two studies cast doubt on the overall cost-effectiveness of this strategy.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Nevirapine During Labor and in the Neonate Significantly Improves Zidovudine Prophylaxis for the Prevention of Perinatal HIV Transmission: Results of PHPT-2 First Interim Analysis (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Let Nevirapine Do What It Does Best (March 2002)
Why recent doubts about widespread use of the drug are unfounded.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Boehringer-Ingelheim Works to Make Nevirapine Available to Prevent Mother-to-Child Transmission of HIV (October 1, 2001)
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Preventing Mother-to-Child HIV Transmission (October 25, 2000)
Technical experts recommend use of antiretroviral regimens beyond pilot projects.
From UNAIDS
- The $4 Question (Winter 1999/2000)
One good use for Nevirapine: reducing the rate of perinatal transmission.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Researchers Identify a Simple, Affordable Drug Regimen That Is Highly Effective in Preventing HIV Infection in Infants of Mothers With the Disease (July 14, 1999)
From U.S. National Institute of Allergy and Infectious Diseases
|
|
